About Vasculin-like protein 1
Vasculin-like protein 1 (GPBP1L1) is a protein
from Homo sapiens identified by UniProt accession
Q9HC44, 474 residues long.
MolForge cross-references it against 0 known binders and
38 disease associations.
Target properties
| Protein name | Vasculin-like protein 1 |
| UniProt accession | Q9HC44 |
| Gene | GPBP1L1 |
| Organism | Homo sapiens |
| Length | 474 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (38)
Diseases linked to this target (Open Targets).
- body mass index · score 0.13
- spinal stenosis · score 0.11
- age-related hearing impairment · score 0.11
- brain measurement · score 0.10
- body fat percentage · score 0.10
- platelet count · score 0.10
- body height · score 0.10
- apolipoprotein A 1 measurement · score 0.09
- cortical surface area measurement · score 0.09
- serum gamma-glutamyl transferase measurement · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9HC44-F1 | alphafold | PREDICTED | 54.40 | — |
Amino-acid sequence (474 residues)
MAQHDFVPAW LNFSTPQSAK SPTATFEKHG EHLPRGEGRF GVSRRRHNSS DGFFNNGPLR TAGDSWHQPS LFRHDSVDSG VSKGAYAGIT GNPSGWHSSS RGHDGMSQRS GGGTGNHRHW NGSFHSRKGC AFQEKPPMEI REEKKEDKVE KLQFEEEDFP SLNPEAGKQH QPCRPIGTPS GVWENPPSAK QPSKMLVIKK VSKEDPAAAF SAAFTSPGSH HANGNKLSSV VPSVYKNLVP KPVPPPSKPN AWKANRMEHK SGSLSSSRES AFTSPISVTK PVVLASGAAL SSPKESPSST TPPIEISSSR LTKLTRRTTD RKSEFLKTLK DDRNGDFSEN RDCDKLEDLE DNSTPEPKEN GEEGCHQNGL ALPVVEEGEV LSHSLEAEHR LLKAMGWQEY PENDENCLPL TEDELKEFHM KTEQLRRNGF GKNGFLQSRS SSLFSPWRST CKAEFEDSDT ETSSSETSDD DAWK
Explore Vasculin-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets